Little Rock, AR – According to filings with the U.S. Securities and Exchange Commission, NuShores Biosciences is raising $6,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sharon Ballard played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NuShores Biosciences
NuShores Biosciences, LLC (NuShores), founded in 2014, was formed to commercialize patented bone and tissue regeneration technologies developed at the University of Arkansas at Little Rock from over $9 million in grant research to date. We have recruited nationally recognized business, technology and medical experts for advisors, directors, and future senior executives. NuShores vision is to improve the global quality of life for people suffering from bone loss. NuShores NuCressT scaffold offers many benefits not achieved by currently marketed bone regeneration products, promising better treatment outcomes to millions with severe bone injuries. Studies suggest that this licensed, patented technology will deliver improved solutions for bone regeneration while cutting healthcare costs, lowering treatment risks, and reducing healing time.

To learn more about NuShores Biosciences, visit http://nushores.com/

Contact:
Sharon Ballard, Chief Executive Officer
602-909-9570
sharon@nushores.com
https://www.linkedin.com/in/sharon-ballard-81026b83/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved